
La Beaute Inc.
LABIFiledLa Beaute Inc. · Nasdaq Capital Market · Research source · S-1 · 2026-08-31
IPO research
La Beaute Inc. has filed a preliminary S-1 to offer 10,000,000 common shares at a fixed price of $5.00 per share, subject to Nasdaq listing approval.
Full source-backed summary
La Beaute Inc. is a newly formed, pre-operating or minimally operating medical-aesthetic platform seeking to raise up to $50 million gross through a 10 million-share IPO at $5.00 per share. The filing contains significant blank financial, dilution, expense, allocation and underwriting information, and the Nasdaq listing is not yet approved.
La Beaute Inc. has filed a preliminary S-1 to offer 10,000,000 common shares at a fixed price of $5.00 per share, subject to Nasdaq listing approval.
- Business and development direction
La Beaute Inc.
Current business Future development
Key risks
Risk 1
The listing application only reserves the ticker and does not assure Nasdaq approval.
Risk 2
The company states that investors may lose their entire investment and that subscription funds generally are non-refundable after acceptance.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
The preliminary filing leaves the underwriter appointment or name open.
IPO CAPITAL QUALITY
Basis and evidence
S-1 · 2026-08-31
La Beaute Inc. has filed a preliminary S-1 to offer 10,000,000 common shares at a fixed price of $5.00 per share, subject to Nasdaq listing approval.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Offered common shares | 10,000,000 | Shares |
| Fixed offering price per common share | $5.00 | $ / share |
Source and calculation
Primary common-share offering summary; Securities Being Offered: 10,000,000 Common Shares, par value $0.0001 per share.; Offering price per share: We will sell the shares at a fixed price of $5.00 per share for the duration of this Offering.; proposed terms as printed; no security conversion, inferred proceeds or equity value. Figures retain their stated source scenario and conditions.
Primary common-share offering summary; Securities Being Offered: 10,000,000 Common Shares, par value $0.0001 per share.; Offering price per share: We will sell the shares at a fixed price of $5.00 per share for the duration of this Offering.; proposed terms as printed; no security conversion, inferred proceeds or equity value.
SEC table 6 row 2 columns 2; source 46217:50836; SHA256 1bf76e25c4621f209a65b378a37cad822d58d511fa0d6b0d6180c5c9831a4cd1; vertical offering context cells 1:2,2:2,3:2 ↗Primary common-share offering summary; Securities Being Offered: 10,000,000 Common Shares, par value $0.0001 per share.; Offering price per share: We will sell the shares at a fixed price of $5.00 per share for the duration of this Offering.; proposed terms as printed; no security conversion, inferred proceeds or equity value. Figures retain their stated source scenario and conditions.
Primary common-share offering summary; Securities Being Offered: 10,000,000 Common Shares, par value $0.0001 per share.; Offering price per share: We will sell the shares at a fixed price of $5.00 per share for the duration of this Offering.; proposed terms as printed; no security conversion, inferred proceeds or equity value.
SEC table 6 row 3 columns 2; source 46217:50836; SHA256 1bf76e25c4621f209a65b378a37cad822d58d511fa0d6b0d6180c5c9831a4cd1; vertical offering context cells 1:2,2:2,3:2 ↗Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Use of proceeds | Source-linked structured inputs are not yet available. Open filing ↗ |
Dilution and valuation
Reported figures remain on their stated basis. Exact compatible price and whole-issuer post-offer inputs are required for calculations.
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Post-offer common stock — as disclosed | 210,000,000 | — | |
| Pre-offer Common stock — as disclosed | 200,000,000 | — | |
| Offered common shares | 10,000,000 | — | |
| Fixed offering price per common share | — | $5.00 |
Basis and evidence ↗
Prospectus share summary; Number of shares of common stock outstanding after the offering of common stock; 210,000,000 shares of common stock will be issued and outstanding if we sell all of the shares we are offering, and no shares of Preferred Stock will be issued and outstanding.; selected security: common stock; selected scenario: as disclosed; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Number of shares of common stock outstanding before the offering of common stock; 200,000,000 shares of Common stock.; selected security: Common stock; selected scenario: as disclosed; separately stated forfeiture or conversion is not applied to this printed pre-offer count; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Primary common-share offering summary; Securities Being Offered: 10,000,000 Common Shares, par value $0.0001 per share.; Offering price per share: We will sell the shares at a fixed price of $5.00 per share for the duration of this Offering.; proposed terms as printed; no security conversion, inferred proceeds or equity value.
Primary common-share offering summary; Securities Being Offered: 10,000,000 Common Shares, par value $0.0001 per share.; Offering price per share: We will sell the shares at a fixed price of $5.00 per share for the duration of this Offering.; proposed terms as printed; no security conversion, inferred proceeds or equity value. Figures retain their stated source scenario and conditions.
Exact input · Fixed offering price per common share: $5
Share-count comparison
Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.
Source ↗IPO valuation scenario simulator
Source inputs required
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Source ↗Source and calculation ↗
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-08-31
Relationship filters
Select for details · La Beaute Inc.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Harmony Medical Group LimitedBeneficial ownership | — | 100%Beneficial | — | Percentage of Ownership before Offering |
| Harmony Medical Group LimitedBeneficial shares | 200,000,000 | — | — | Common Stock Owned before Offering |
| Common Stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; Common Stock; full source conditions retained; not a holder voting percentage, ownership amount or controller finding |
Source and calculation ↗
Exact source ownership column: Percentage of Ownership before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Ownership before Offering; source holder: Harmony Medical Group Limited
Exact source ownership column: Common Stock Owned before Offering; holders may overlap; not an additive partition
Raw source column: Common Stock Owned before Offering; source holder: Harmony Medical Group Limited
Literal source per-share voting entitlement; Common Stock; full source conditions retained; not a holder voting percentage, ownership amount or controller finding
Each holder of shares of Common Stock is entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. Cumulative voting rights do not apply to Common Stock. Additionally, holders of any class or series of stock do not have preemptive rights to subscribe for, purchase, or receive any new or additional issuances of shares or convertible securities, regardless of whether such issuances are authorized now or in the future, or whether they are issued for money, for consideration other than money, or as a dividend.
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Source lock-up conditions
Literal month restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| Our directors, executive officers, and shareholdersAfter date of this prospectus · Source conditions apply | 6 months |
Source and calculation
Our directors, executive officers, and shareholders have entered into agreements, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase, or otherwise dispose of, directly or indirectly, any of our Common stock or other securities for a period of six months from the date of this prospectus. This includes refraining from entering into any swap or other agreement that transfers, in whole or in part, the economic consequences of ownership of such securities without the prior written consent of the representative. Additionally, the Company is prohibited from conducting any offerings during this period and from re-pricing or changing the terms of existing options and warrants.
SEC lock-up paragraph; source 171083:171997; SHA256 6f99e87588164e58fd26bf2a99221e64fb26957b2156f41b95d67ccce215eda0 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
date of this prospectus
- Our directors, executive officers, and shareholdersOur directors, executive officers, and shareholders have entered into agreements, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase, or otherwise dispose of, directly or indirectly, any of our Common stock or other securities for a period of six months from the date of this prospectus. This includes refraining from entering into any swap or other agreement that transfers, in whole or in part, the economic consequences of ownership of such securities without the prior written consent of the representative. Additionally, the Company is prohibited from conducting any offerings during this period and from re-pricing or changing the terms of existing options and warrants.
| Holder / event | Term / date | Conditions |
|---|---|---|
| Our directors, executive officers, and shareholders | 6 months | Our directors, executive officers, and shareholders have entered into agreements, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase, or otherwise dispose of, directly or indirectly, any of our Common stock or other securities for a period of six months from the date of this prospectus. This includes refraining from entering into any swap or other agreement that transfers, in whole or in part, the economic consequences of ownership of such securities without the prior written consent of the representative. Additionally, the Company is prohibited from conducting any offerings during this period and from re-pricing or changing the terms of existing options and warrants. |
Basis and evidence
Our directors, executive officers, and shareholders have entered into agreements, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase, or otherwise dispose of, directly or indirectly, any of our Common stock or other securities for a period of six months from the date of this prospectus. This includes refraining from entering into any swap or other agreement that transfers, in whole or in part, the economic consequences of ownership of such securities without the prior written consent of the representative. Additionally, the Company is prohibited from conducting any offerings during this period and from re-pricing or changing the terms of existing options and warrants.
SEC lock-up paragraph; source 171083:171997; SHA256 6f99e87588164e58fd26bf2a99221e64fb26957b2156f41b95d67ccce215eda0 ↗The draft leaves cash, assets, revenue and loss amounts blank. Nearby no-loss wording does not supply those amounts.
Financial quality
| Calculation | Reported value | Reference |
|---|---|---|
| Total assets | Blank in the filed draft | As of July 31, 2026 |
| Cash and cash equivalents | Blank in the filed draft | As of July 31, 2026 |
| Revenue | Blank in the filed draft | For the year ended July 31, 2026 |
| Net income / (loss) | Blank in the filed draft | For the period ended July 31, 2026 |
| Working capital / (deficit) | Blank in the filed draft | For the period ended July 31, 2026 |
Source and limits
These source states do not establish other financial fields or a zero balance.
The draft also contains separate financial claims. They have not been reconciled into reported figures.
As of July 31, 2026, we had total assets of $[ ] and cash and cash equivalents of $[ ].
0002151905-26-000001 · 121341:121478 · SHA256 79a2a636b1ca6a2b5808e75896b4e6bd9b665c7b888589ee9d767e59383b9e56 ↗For the year ended July 31, 2026, we realized revenues of $[ ], and a gross profit of $[ ].
0002151905-26-000001 · 122027:122169 · SHA256 277698e2f3059e3f5676dfcf7924f8987908c317c3cc0abd091409fc78ea3346 ↗The financial statements included herein have been prepared on the assumption that the Company will continue as a going concern. For the period ended July 31, 2026, the Company recorded a net loss of $[ ], which led to an accumulated deficit of $[ ] and a working capital of $[ ].
0002151905-26-000001 · 124382:124720 · SHA256 f67cebc46a5b81f32afcda8822b187ac8bfe0175df23fb7a74e15b282c39783c ↗As of July 31, 2026, we have no liabilities. We have a shareholders’ equity of $[ ].
121700:121840 · SHA256 7ac9d5572405c9f497675b65ce240c3fd4e851bb8388c06e7cc5a997dab66b70 ↗For the year ended July 31, 2026, we incurred no net loss.
122804:122912 · SHA256 b3ead12f6e5903034710c835cee81231e6616f37bced82eb98d28cb020ffec15 ↗Financial quality and runway
Financial quality and runway
The supplied evidence does not provide reliable complete financial amounts. The filing states no liabilities and no net loss for the year ended July 31, 2026, but key amounts remain placeholders and the company discloses substantial doubt about continuing as a going concern.
EvidenceFinancial review 1Assets, cash, revenue, gross profit, SG&A, cash flows and equity amounts are blank.
+
Assets, cash, revenue, gross profit, SG&A, cash flows and equity amounts are blank.
EvidenceFinancial review 2The filing states substantial doubt about going concern within one year from issuance of the financial statements.
+
The filing states substantial doubt about going concern within one year from issuance of the financial statements.
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
No source-comparable material changes identified in this report.
S-10002151905-26-000001 ↗
Loading filing history…
The listing application only reserves the ticker and does not assure Nasdaq approval.
- Evidence
- PRELIMINARY PROSPECTUS ↗
The company states that investors may lose their entire investment and that subscription funds generally are non-refundable after acceptance.
- Evidence
- RISK FACTORS ↗